Bioplant. Inc 20 North Main Street South Norwalk, CT 06854 Ph 203-899-0466 Fax 203-899-0278 1-800-432-4487 Bioplant, Inc. (Bioplant® or "the Company") is a Delaware corporation formed in November 1992 by Dr. Arthur Ashman, D.D.S, to market Hard Tissue Replacement (trademarked HTR® by the Company) for all general dentistry and oral restorative surgery applications. HTR, a patented bone substitute used in dental and orthopedic applications, is unique among bone substitutes in that it is bone conductive material (i.e., a bone promoter). When placed into a bleeding site in which bone was previously present, HTR creates a matrix through which bone regenerates and grows. HTR is a non resorbable microporous calcium layered co-polymer of polyhydroxylethylmethacrylate and polymethylmethacrylate which has been shown to be non-inflammatory, biocompatible, osteogenic and radiopague, with weight-bearing characteristics. In 1986, U.S. Surgical Corporation, Inc. purchased the assets of Medical Biological Sciences, Inc. (MBS®), a research and development company founded by Dr. Ashman which developed HTR. In 1992 Bioplant acquired the exclusive right to market HTR worldwide in the field of dentistry. Bioplant Chairman Dr. Arthur Ashman, the co-inventor of HTR, is a pioneer in the field of restorative and implant dentistry. His numerous articles and studies on synthetic bone and its applications in dentistry have been published widely in respected dental and medical journals. Since its market introduction, HTR has been successfully used by dental practitioners in over 150,000 documented procedures worldwide. Clinical studies of HTR on both human and animal tissues have been conducted at Mt. Sinai Hospital, Columbia University, the University of Tennessee, Battelle Laboratories, Weizman Institute Tel Aviv, New York University, Loma Linda, UCLA and the University of Indiana. In every clinical test, there has been no significant adverse effects or rejection of the material. Bioplant has never received a complaint concerning HTR. HTR has received Food and Drug Administration ("FDA") 510 K approval for dental applications including Jawbone Preservation and Maintenance, Implant Dentistry, Ridge Augmentation and treatment of Periodontal Defects. Bioplant recently received the CE mark for HTR to market and sell in the European market. HTR generated over $4 million in sales worldwide in 1997 and is the leading synthetic bone sold in the dentistry field. Bioplant is now moving to develop new products supporting the use of HTR, especially with the use of implants. HTR has also more recently been discovered to have additional applications appropriate for the Orthopedic, Neurology, Urology and Cosmetic Surgery markets.